TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trialResearch in context

Summary: Background: Trifluridine-tipiracil has shown a survival benefit compared with placebo in patients with chemorefractory metastatic esophago-gastric adenocarcinoma. We aimed to compare the efficacy of trifluridine-tipiracil plus bevacizumab vs trifluridine-tipiracil monotherapy in pre-treate...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Lene Baeksgaard Jensen, Mette Yilmaz, Marianne Nordsmark, Sören Möller, Ida Coordt Elle, Morten Ladekarl, Camilla Qvortrup, Per Pfeiffer
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2024-04-01
Sarja:	EClinicalMedicine
Aiheet:	Gastroesophageal Cancer Metastatic Trifluridine-tipiracil Bevacizumab
Linkit:	http://www.sciencedirect.com/science/article/pii/S2589537024001007
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!